Biogen.

Biogen will spend more than $7 billion to buy Texas-based Reata Pharmaceuticals and bolster its rare disease treatments. Reata's FDA-approved Skyclarys (omaveloxolone) is the only approved treatment for Friedreich's ataxia in the U.S., and the...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT